All In Biotech

Free tool

FAERS Monitor: Epysqli

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761340 or its brand name (Epysqli, Eculizumab-Aagh). Reports on generic versions are filed under their own applications.

Reports

27

Serious

24

89% of reports

Hospitalization

11

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use6
  • abortion spontaneous2
  • condition aggravated2
  • death2
  • hypertension2
  • immunodeficiency2
  • maternal exposure during pregnancy2
  • acute kidney injury1
  • antiphospholipid syndrome1
  • atypical haemolytic uraemic syndrome1
  • back pain1
  • blood pressure increased1
  • candida infection1
  • cerebrovascular accident1
  • conjunctival hyperaemia1

Reports by year received

View as table
YearReports
20244
20255
202618

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,132 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
atypical haemolytic uraemic syndrome1960.3140.1239
antiphospholipid syndrome1484.970.8120
conjunctival hyperaemia1218.631.954
immunodeficiency2104.527.5115
candida infection146.16.711
abortion spontaneous238.910.241
maternal exposure during pregnancy217.54.617
hypertension27.41.96
off label useSignal65.32.618
condition aggravated25.11.43
blood pressure increased15.10.70
acute kidney injury15.10.70
cerebrovascular accident14.60.70
back pain13.40.50
death21.80.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.